1
|
Hao S, Wang JH, Hou L, Liang JW, Yan JH, Niu YF, Li XY, Sun Q, Meng FH. Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents. Bioorg Chem 2024; 151:107686. [PMID: 39111120 DOI: 10.1016/j.bioorg.2024.107686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2024] [Revised: 07/25/2024] [Accepted: 07/29/2024] [Indexed: 08/30/2024]
Abstract
A series of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors were designed and synthesized by heterocyclic-containing tail approach. The inhibitory activities against four human epidermal growth factor receptor (HER) isozymes (EGFR, HER-2, HER-3 and HER-4) of all new compounds so designed were investigated in vitro. Compound 12k was found to be the most effective and rather selective dual-target inhibitor of EGFR and HER-2 with inhibitory constant (IC50) values of 6.15 and 9.78 nM, respectively, which was more potent than the clinical used agent Lapatinib (IC50Â =Â 8.41 and 9.41 nM). Meanwhile, almost all compounds showed excellent antiproliferative activities against four cancer cell models (A549, NCI-H1975, SK-BR-3 and MCF-7) and low damage to healthy cells. Among them, compound 12k also exhibited the most prominent antitumor activity. Moreover, the hit compound 12k could bind to EGFR and HER-2 stably in molecular docking and dynamics studies. The following wound healing assay revealed that compound 12k could inhibit the migration of SK-BR-3 cells. Further studies found that compound 12k could arrest cell cycle in the G0/G1 phase and induce SK-BR-3 cells apoptosis. Notably, compound 12k could effectively inhibit breast cancer growth with little toxicity in the SK-BR-3 cell xenograft model. Taken together, in vitro and in vivo results disclosed that compound 12k had high drug potential as a dual-target inhibitor of EGFR/HER-2 to inhibit breast cancer growth.
Collapse
Affiliation(s)
- Shuang Hao
- School of Pharmacy, China Medical University, Shenyang 110122, PR China
| | - Jia-Hui Wang
- School of Pharmacy, China Medical University, Shenyang 110122, PR China
| | - Liang Hou
- School of Pharmacy, China Medical University, Shenyang 110122, PR China
| | - Jing-Wei Liang
- School of Pharmacy, China Medical University, Shenyang 110122, PR China; School of Pharmacy, Hainan Medical University, Haikou 571199, PR China
| | - Jing-Han Yan
- School of Pharmacy, China Medical University, Shenyang 110122, PR China
| | - Yi-Fan Niu
- School of Pharmacy, China Medical University, Shenyang 110122, PR China
| | - Xin-Yang Li
- School of Pharmacy, China Medical University, Shenyang 110122, PR China; Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, PR China
| | - Qi Sun
- School of Pharmacy, China Medical University, Shenyang 110122, PR China.
| | - Fan-Hao Meng
- School of Pharmacy, China Medical University, Shenyang 110122, PR China.
| |
Collapse
|
2
|
Azimi M, Najafi Z, Bahmani A, Chehardoli G, Iraji A. Synthesis and biological assessment of novel 4H-chromene-3-carbonitrile derivatives as tyrosinase inhibitors. BMC Chem 2024; 18:187. [PMID: 39342248 PMCID: PMC11439338 DOI: 10.1186/s13065-024-01305-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2024] [Accepted: 09/19/2024] [Indexed: 10/01/2024] Open
Abstract
Excessive activity of the tyrosinase enzyme during melanogenesis results in hyperpigmentation in the skin. To address this issue, there is a need to develop effective tyrosinase inhibitors as a treatment for hyperpigmentation. In this study, we synthesized some novel 4H-chromene-3-carbonitrile compounds (6a-o) and assessed their inhibitory activities against tyrosinase, comparing them with kojic acid, which is known as a positive control. Compound 6f emerged as the most effective inhibitor, with an IC50 of 35.38â±â2.12 ”M. Kinetic studies of 6f exhibited competitive inhibition, with Ki = 16.15 ”M. Molecular docking studies highlighted the importance of Ï-Ï stacking and hydrogen bonding interactions within the binding site. Molecular dynamics simulations showed that the R-enantiomer 6f exhibited superior binding stability compared to the S-enantiomer, with a lower standard deviation of RMSD and more persistent interactions with the key active site residues. These findings underscore the potential of the R-enantiomer of compound 6f as a potent tyrosinase inhibitor and provide insights for developing effective treatments for hyperpigmentation and related skin conditions.
Collapse
Affiliation(s)
- Mohammad Azimi
- Department of Medicinal Chemistry, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Zahra Najafi
- Department of Medicinal Chemistry, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Asrin Bahmani
- Department of Medicinal Chemistry, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Gholamabbas Chehardoli
- Department of Medicinal Chemistry, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
| | - Aida Iraji
- Department of Persian Medicine, School of Medicine, Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
| |
Collapse
|
3
|
Faizan S, Talath S, Wali AF, Hani U, Haider N, Mandal SP, Kumar BRP. Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer via EGFR inhibition: molecular design, synthesis, analysis and screening. RSC Adv 2024; 14:11368-11387. [PMID: 38595721 PMCID: PMC11002980 DOI: 10.1039/d4ra01424c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2024] [Accepted: 03/29/2024] [Indexed: 04/11/2024] Open
Abstract
A series of novel symmetrical and asymmetrical dihydropyridines (HD 1-15) were designed, subjected to in silico ADMET prediction, synthesized, analyzed by IR, NMR, Mass analytical techniques and evaluated against epidermal growth factor receptor (EGFR) as inhibitors against Breast cancer. The results of predicted ADMET studies demonstrated the drug-likeness properties of the reported compounds. The in vitro cytotoxicity assessment of the synthesized compounds revealed that all of them showed good activity (IC50 ranging from 16.75 to 66.54 ΌM) towards MCF-7 breast cancer cells compared to the standard drug, Lapatinib (IC50 = 2.02 ΌM). Among these, compounds HD-6, HD-7, and HD-8 displayed the most potent activity with IC50 value of 21.26, 16.75, and 18.33 ΌM, respectively. Cytotoxicity of all compounds was tested on normal vero cells for comparison at different concentrations using the MTT assay. In addition to the MTT assay, the potent dihydropyridines derivatives were screened for EGFRwt kinase inhibition assay at concentrations ranging from 1 nM to 360 nM. Among the three compounds tested, HD-8 showed reasonably good inhibition with an IC50 value of 15.90 ± 1.20 nM compared to a standard Lapatinib IC50 value of 10.28 ± 1.01 nM. Based on the molecular docking study against EGFR, the most active derivatives HD-7 and HD-8 were docked against the active site of the protein and showed better binding affinity than the standard lapatinib. Additionally, molecular dynamics (MD) simulations were performed to explore the stability of the protein-ligand complex, its dynamic behavior, and the binding affinity.
Collapse
Affiliation(s)
- Syed Faizan
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Constituent College of JSS Academy of Higher Education & Research Mysuru 570015 India +91-821-2548359 +91-821-2548353
| | - Sirajunisa Talath
- Department of Pharmaceutical Chemistry, RAK Medical & Health Sciences University Ras Al Khaimah UAE
| | - Adil Farooq Wali
- Department of Pharmaceutical Chemistry, RAK Medical & Health Sciences University Ras Al Khaimah UAE
| | - Umme Hani
- Department of Pharmaceutics, College of Pharmacy, King Khalid University Abha Saudi Arabia
| | - Nazima Haider
- Department of Pathology, College of Medicine, King Khalid University Abha Saudi Arabia
| | - Subhankar P Mandal
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Constituent College of JSS Academy of Higher Education & Research Mysuru 570015 India +91-821-2548359 +91-821-2548353
| | - B R Prashantha Kumar
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Constituent College of JSS Academy of Higher Education & Research Mysuru 570015 India +91-821-2548359 +91-821-2548353
| |
Collapse
|
4
|
Das A, Sarangi M, Jangid K, Kumar V, Kumar A, Singh PP, Kaur K, Kumar V, Chakraborty S, Jaitak V. Identification of 1,3,4-oxadiazoles as tubulin-targeted anticancer agents: a combined field-based 3D-QSAR, pharmacophore model-based virtual screening, molecular docking, molecular dynamics simulation, and density functional theory calculation approach. J Biomol Struct Dyn 2023:1-19. [PMID: 37695635 DOI: 10.1080/07391102.2023.2256876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 09/02/2023] [Indexed: 09/12/2023]
Abstract
Cancer is one of the most prominent causes of death worldwide and tubulin is a crucial protein of cytoskeleton that maintains essential cellular functions including cell division as well as cell signalling, that makes an attractive drug target for cancer drug development. 1,3,4-oxadiazoles disrupt microtubule causing G2-M phase cell cycle arrest and provide anti-proliferative effect. In this study, field-based 3D-QSAR models were developed using 62 bioactive anti-tubulin 1,3,4-oxadiazoles. The best model characterized by PLS factor 7 was rigorously validated using various statistical parameters. Generated 3D-QSAR model having high degree of confidence showed favourable and unfavourable contours around 1,3,4-oxadiazole core that assisted in defining proper spatial positioning of desired functional groups for better bioactivity. A five featured pharmacophore model (AAHHR_1) was developed using same ligand library and validated through enrichment analysis (BEDROC160.9 value = 0.59, Average EF 1%â=â27.05, and AUC = 0.74). Total 30,212 derivatives of 1,3,4-oxadiazole obtained from PubChem database was prefiltered through validated pharmacophore model and docked in XP mode on binding cavity of tubulin protein (PDB code: 1SA0) which led into the identification of 11 HITs having docking scores between -7.530 and -9.719âkcal/mol while the reference compound Colchicine exerted docking score of -7.046âkcal/mol. Following the analysis of MM-GBSA and ADME studies, HIT1 and HIT4 emerged as the two promising hits. To verify their thermodynamic stability at the target site, molecular dynamic simulations were carried out. Both HITs were further subjected to DFT analysis to determine their HOMO-LUMO energy gap for ensuring their biological feasibility. Finally, molecular docking based structural exploration for 1,3,4-oxadiazoles to set up a lead of Formula I for further advancements of tubulin polymerization inhibitors as anti-cancer agents.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Agnidipta Das
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Manaswini Sarangi
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Kailash Jangid
- Department of Chemistry, Central University of Punjab, Bathinda, India
| | - Vijay Kumar
- Department of Chemistry, Central University of Punjab, Bathinda, India
| | - Amit Kumar
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Praval Pratap Singh
- Department of Computational Sciences, School of Basic Sciences, Central University of Punjab, Bathinda, India
| | - Kamalpreet Kaur
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Vinod Kumar
- Department of Chemistry, Central University of Punjab, Bathinda, India
| | - Sudip Chakraborty
- Department of Computational Sciences, School of Basic Sciences, Central University of Punjab, Bathinda, India
| | - Vikas Jaitak
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| |
Collapse
|
5
|
Sidhom PA, El-Bastawissy E, Ibrahim MAA, Shawky AM, Salama A, El-Moselhy T. Mechanistic Insight of Synthesized 1,4-Dihydropyridines as an Antidiabetic Sword against Reactive Oxygen Species. J Med Chem 2023; 66:991-1010. [PMID: 36584305 DOI: 10.1021/acs.jmedchem.2c01818] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The pharmacologically privileged DHP derivatives were synthesized using the pragmatic multicomponent Hantzsch synthesis to screen the antidiabetic activity. Initially, the candidates were screened using an in vivo blood glucose test, where compound 8b showed the most prominent antidiabetic effect (% potency = 218%) compared to glimepiride. Then, a propositioned structure-activity relationship study was executed to reveal that longer side chains decreased the DHP's antidiabetic action. Mechanistically, compound 8b diminished ROS in ÎČ-cells and muscle cells simultaneously, which was proved by enhanced serum biochemical markers. Also, compound 8b decreased blood glucose by α-glucosidase inhibition (IC50 = 4.48 ± 0.32 ÎŒM), compared to acarbose (7.40 ± 0.41 ÎŒM), based selectively on the plasma window of 8b. Acarbose demonstrated auspicious inhibitor activity according to the binding affinity (ÎGbinding), which was slightly lower than that of compound 8b (-54.7 and -46.8 kcal/mol, respectively). During the 100 ns molecular dynamics simulations, the structural and energetic assessments exposed the high consistency of compound 8b to bind to the α-glucosidase.
Collapse
Affiliation(s)
- Peter A Sidhom
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, 31527 Tanta, Egypt
| | - Eman El-Bastawissy
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, 31527 Tanta, Egypt
| | - Mahmoud A A Ibrahim
- Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt
| | - Ahmed M Shawky
- Science and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia
| | - Abeer Salama
- Pharmacology Department, National Research Centre (NRC), 33 El-Bohouth St. (Former El-Tahrir St.), 12622 Dokki, Giza, Egypt
| | - Tarek El-Moselhy
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, 31527 Tanta, Egypt
| |
Collapse
|
6
|
Saad MH, El-Moselhy TF, S El-Din N, Mehany ABM, Belal A, Abourehab MAS, Tawfik HO, El-Hamamsy MH. Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies. J Enzyme Inhib Med Chem 2022; 37:2489-2511. [PMID: 36093880 PMCID: PMC9481151 DOI: 10.1080/14756366.2022.2120478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Two new series of symmetric (1a-h) and asymmetric (2a-l) 1,4-DHP derivatives were designed, synthesised, and evaluated as anticancer agents. In vitro anticancer screening of target compounds via National cancer institute âNCIâ revealed that analogues 1g, 2e, and 2l demonstrated antiproliferative action with mean growth inhibition percentage âGI%â = 41, 28, and 64, respectively. The reversal doxorubicin (DOX) effects of compounds 1g, 2e, and 2l were examined and illustrated better cytotoxic activity with IC50 =1.12, 3.64, and 3.57 ”M, respectively. The most active anticancer analogues, 1g, 2e, and 2l, were inspected for their putative mechanism of action by estimating their epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), and Brutonâs tyrosine kinase (BTK) inhibitory activities. Furthermore, the antimicrobial activity of target compounds was assessed against six different pathogens, followed by determining the minimum inhibitory concentration âMICâ values for the most active analogues. Molecular docking study was achieved to understand mode of interactions between selected inhibitors and different biological targets.
Collapse
Affiliation(s)
| | - Tarek F El-Moselhy
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt
| | - Nabaweya S El-Din
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt
| | - Ahmed B M Mehany
- Zoology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt
| | - Amany Belal
- Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.,Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia
| | - Mohammed A S Abourehab
- Department of Pharmaceutics, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.,Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Minia University, Minia, Egypt
| | - Haytham O Tawfik
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt
| | - Mervat H El-Hamamsy
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt
| |
Collapse
|
7
|
Khaled A, Stiti MZ, Habila T, Ferkhi M, Pirotte B, Pireaux JJ, Khelili S. Synthesis and characterization of La1âxSrxMn1-yZnyO3 perovskites as an efficient and recoverable catalyst for the Hantzsch reaction. J CHEM SCI 2022. [DOI: 10.1007/s12039-022-02084-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
8
|
Kumar R, Yadav N, Jain H, Deswal N, Upadhyay RK, Leekha A, Verma AK, Kareem A, Chikati R, Kumar LS. MicrowaveâAssisted Synthesis of 4âArylâ1,4âdihydropyridines as Potent Anticancer Agent and Their
InâSilico Studies. ChemistrySelect 2022. [DOI: 10.1002/slct.202104129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Rakesh Kumar
- Bioorganic Laboratory Department of Chemistry University of Delhi Delhi 110007 India
| | - Neha Yadav
- Bioorganic Laboratory Department of Chemistry University of Delhi Delhi 110007 India
| | - Harshita Jain
- Bioorganic Laboratory Department of Chemistry University of Delhi Delhi 110007 India
| | - Nidhi Deswal
- Bioorganic Laboratory Department of Chemistry University of Delhi Delhi 110007 India
| | | | - Ankita Leekha
- Nano Biotech Laboratory Department of Zoology Kirori Mal College University of Delhi Delhi 110007 India
| | - Anita Kamra Verma
- Nano Biotech Laboratory Department of Zoology Kirori Mal College University of Delhi Delhi 110007 India
| | | | - Rajasekhar Chikati
- Department of Biochemistry Yogivemana University Kadpa- 516005 Andhra Pradesh India
| | | |
Collapse
|
9
|
Mineyeva IV, Faletrov YV, Starovoitova VA, Shkumatov VM. New 1,4-Dihydropyridines. Optimization of the Synthesis and In Silico Analysis of Biological Activity. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2022. [DOI: 10.1134/s1070428022030034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|